国药现代：产品取得注册证

Group 1 - The core point of the article is that Guoyao Modern has received approval from the National Medical Products Administration for its product, Hydromorphone Hydrochloride Injection, which is expected to impact its revenue positively [1] - Guoyao Modern's revenue composition for the year 2024 is as follows: 49.84% from formulations, 47.53% from intermediates and active pharmaceutical ingredients, 2.44% from other businesses, and 0.19% from health-related sectors [1] - As of the report, Guoyao Modern has a market capitalization of 13.8 billion yuan [1]